Options
ATYR options chain
Explore expirations, strikes, liquidity, live quotes and Greeks in the context of the same company overview.
Options Chain SnapshotA bounded snapshot of up to 200 active contracts in the displayed expiration and strike window. Close and open interest are reference fields, not live quotes.
Up to 200 active ATYR contracts expiring in the next 7–45 days, with strikes within ±25% of the current price.
No active options contracts for ATYR in this window right now.
- Source
- US listed-options contracts feed
- Observed
- Cadence
- Five-minute cached contract snapshot
- Status
- fresh
Live Quotes & GreeksThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
Options Ideas & Decision IntelligenceThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
Asset BackgroundSource-supported background about this asset. The sources and review status are listed with the reference.
ATYR options refer to aTYR PHARMA INC as their underlying. aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
AI-selected reference, checked against source evidence · Evidence observed
Frequently Asked QuestionsSource-linked answers to common questions about this asset. Check the evidence observation date and whether the reference was reviewed by a person.
- What business does aTYR PHARMA INC operate?
- aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
- How do ATYR options relate to the underlying company?
- The published options record identifies ATYR as an underlying symbol. Options contracts reference that underlying; expiration, strike and option type define each separate contract.
What to WatchAI-assisted topics for further research about this asset. These are educational prompts, not trading signals or recommendations.
- Business activities described in the company reference
- Original company disclosures and industry classification